treatment options for patients with lbcl who relapse or are refractory to initial treatment
Published 2 weeks ago • 31 plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
3:27
therapeutic options for patients with primary refractory/early relapsed dlbcl
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
2:13
treatment approaches for patients with r/r aml and the importance of preventing relapse
-
1:52
novel options for patients with cll who relapse after treatment with btk inhibitors and venetoclax
-
3:12
an analysis of shared treatment decision-making in patients with r/r dlbcl
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:02
the changing standard of care in dlbcl
-
1:52
an insight into the optimal management of patients with dlbcl
-
2:26
feasibility of sequential treatment with cd19-targeted agents in patients with lbcl
-
1:11
treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
-
6:44
the current landscape for the treatment of r/r aml in the post-transplant setting
-
2:38
emerging strategies for the management of relapsed aml
-
2:43
treatment sequencing options for recurrent cll
-
1:51
checkpoint inhibition in the treatment of mpns
-
1:34
updated bsh guidelines for managing dlbcl
-
0:44
is hsct a suitable treatment option for patients with all who have achieved undetectable bcr::abl1?
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity